Just getting to the 2017 finish line wasn't enough for the US FDA. The agency is running through the finish line with the Center for Drug Evaluation and Research's (CDER) approval of four new molecular entity products this past week, breaking its 2015 approval record of 45.
The finishing touch was the greenlight for La Jolla Pharmaceutical Co